VolitionRX Ltd
AMEX: VNRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange Arca
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Cameron Reynolds
- Employees
- 67
- Headquarters
- Henderson, United States
- IPO year
- 2012
- Market cap
- $11.3M
- Website
- https://volition.com
Loading VNRX…
Loading profile data…Frequently asked questions about VNRX
What does VolitionRX Ltd (VNRX) do?
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as se...
Where does VNRX trade?
VolitionRX Ltd (VNRX) trades on the New York Stock Exchange Arca.
What sector is VNRX in?
VolitionRX Ltd (VNRX) operates in the Healthcare sector, specifically in the Medical - Specialties industry.
Who is the CEO of VolitionRX Ltd?
Cameron Reynolds is the chief executive officer of VolitionRX Ltd (VNRX).
Where is VolitionRX Ltd headquartered?
VolitionRX Ltd is headquartered in United States.
Does VNRX pay a dividend?
VolitionRX Ltd (VNRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VNRX go public?
VolitionRX Ltd (VNRX) completed its initial public offering in 2012.